How Software as a Medical Device Is Governed in the United States Digital technologies are transforming healthcare by enabling advanced diagnostics, remote monitoring, and data-driven clinical decisions. When software itself performs a medical function without being embedded in a physical device, it is categorized as Software as a Medical Device (SaMD). In the United States, SaMD is subject to a defined regulatory structure intended to protect patient safety while encouraging responsible innovation. For business owners and decision-makers, understanding how Software as a Medical Device is regulated in the US is a critical step when planning product development or market entry. Defining SaMD Under US Regulations In the US, the Food and Drug Administration (FDA) considers software to be a medical device when it is intended to diagnose, treat, mitigate, cure, or prevent disease, and when it operates independently of hardware medical devices. Examples include clinical decision support software, diagnostic algorithms, and software used for patient monitoring or therapy management. Not all healthcare-related software falls under FDA regulation. The agency applies a regulatory discretion and risk-based assessment to determine whether a software product qualifies as SaMD and how much oversight is required. This distinction helps ensure that regulatory resources are focused on software that has a direct impact on patient outcomes. Risk-Based Classification of SaMD The FDA classifies SaMD into Class I, Class II, or Class III based on the level of risk associated with its intended use. Most SaMD products are categorized as Class II, which typically requires premarket review, while higher-risk applications may be classified as Class III and require more extensive regulatory evaluation. Classification decisions are influenced by factors such as the software’s role in clinical decision-making, the severity of the medical condition involved, and the potential consequences of incorrect output. For example, software that directly informs treatment decisions is subject to stricter oversight than software that provides general health information. FDA Premarket Review Pathways Once classification is established, SaMD developers must follow the appropriate FDA premarket pathway. Common routes include the 510(k) premarket notification process, the De Novo pathway for novel devices, and Premarket Approval (PMA) for high-risk products. Each pathway has specific data and documentation requirements. Submissions generally include detailed descriptions of software functionality, validation and verification testing, risk management documentation, and cybersecurity controls. Developers often review guidance related to US FDA SaMD registration services to better understand how these expectations apply to software-based medical products. Quality Systems and Software Lifecycle Controls The FDA places strong emphasis on controlled software development processes. Manufacturers are expected to demonstrate robust software lifecycle management, including defined requirements, design controls, testing protocols, and change management practices. Standards such as IEC 62304 for medical software lifecycle processes and ISO 14971 for risk management are commonly used to support compliance. Although ISO 13485 is not a mandatory requirement in the US, it is widely recognized as a best-practice framework for managing quality systems in medical device organizations, including those developing SaMD. A structured quality system helps ensure consistency, traceability, and regulatory readiness. Post-Market Monitoring and Ongoing Obligations Regulatory responsibilities for SaMD continue after market entry. Manufacturers are required to monitor real-world performance, manage customer complaints, and report adverse events through the FDA’s Medical Device Reporting system. These post-market activities help regulators identify emerging risks and ensure ongoing product safety. Software updates and cybersecurity enhancements must also be carefully controlled. Changes that affect safety, performance, or intended use may require regulatory notification or additional review. Failure to manage post-market obligations appropriately can lead to compliance actions or enforcement measures. Common Regulatory Challenges for SaMD Developers Many SaMD developers originate from technology or software backgrounds and may be unfamiliar with medical device regulatory expectations. One common challenge is clearly defining the intended use of the software, which directly influences classification and regulatory requirements. Another frequent issue is documentation. Agile development approaches must still produce traceable records that demonstrate compliance with design controls and risk management principles. Cybersecurity planning is also a growing area of regulatory focus, and insufficient controls in this area can delay approvals. Value of Early Regulatory Planning Proactive regulatory planning helps SaMD developers align product design with FDA expectations from the outset. Early understanding of classification, submission pathways, and quality system requirements can reduce delays and minimize the need for rework later in development. Industry discussions often reference experienced advisory organizations such as Operon Strategist when emphasizing the importance of structured regulatory guidance in navigating the US SaMD landscape. Such perspectives reflect the broader understanding that regulatory strategy and technical development must progress together. Global Alignment and Market Considerations The FDA’s approach to SaMD aligns closely with international guidance developed by the International Medical Device Regulators Forum (IMDRF). This alignment supports companies seeking global market access by encouraging harmonized risk assessment and documentation practices. However, US-specific guidance documents and expectations still require careful attention. Conclusion Software as a Medical Device is regulated in the United States through a structured, risk-based framework overseen by the FDA. Classification, premarket review, quality system controls, and post-market oversight all play essential roles in ensuring patient safety and product effectiveness. For business leaders and decision-makers, understanding how Software as a Medical Device is regulated in the US provides a strong foundation for compliant development and sustainable growth in the digital health sector.